Thomas Smith
Stock Analyst at Leerink Partners
(2.31)
# 2,662
Out of 4,974 analysts
67
Total ratings
29.51%
Success rate
14.54%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Thomas Smith
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EQ Equillium | Downgrades: Market Perform | $3 → $1 | $1.91 | -47.64% | 4 | Mar 28, 2025 | |
| QTTB Q32 Bio | Downgrades: Market Perform | $68 → $9 | $1.67 | +438.92% | 2 | Dec 11, 2024 | |
| ACRS Aclaris Therapeutics | Upgrades: Outperform | $2 → $7 | $2.10 | +233.33% | 7 | Nov 19, 2024 | |
| ALMS Alumis | Initiates: Outperform | $29 | $4.51 | +543.02% | 1 | Jul 23, 2024 | |
| RNAC Cartesian Therapeutics | Initiates: Outperform | $39 | $10.75 | +262.79% | 1 | Apr 23, 2024 | |
| SGMT Sagimet Biosciences | Initiates: Outperform | $26 | $7.11 | +265.68% | 1 | Mar 25, 2024 | |
| RAPT RAPT Therapeutics | Downgrades: Market Perform | $80 | $12.93 | +518.72% | 2 | Feb 21, 2024 | |
| ABVX ABIVAX Société Anonyme | Initiates: Outperform | $20 | $88.03 | -77.28% | 1 | Nov 14, 2023 | |
| ARGX argenx SE | Maintains: Outperform | $430 → $435 | $750.78 | -42.06% | 3 | Mar 3, 2023 | |
| IRON Disc Medicine | Initiates: Outperform | $36 | $60.72 | -40.71% | 1 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $7 | $1.75 | +300.00% | 4 | Feb 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $21 | $17.14 | +22.52% | 6 | Feb 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $45 | $18.72 | +140.38% | 2 | Jan 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $6 | $7.01 | -14.41% | 1 | Nov 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $5 → $6 | $5.54 | +8.30% | 2 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $9 → $5 | $0.76 | +557.03% | 3 | Oct 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $17 | $59.44 | -71.40% | 1 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $68 → $64 | $22.85 | +180.15% | 2 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $66 → $70 | $16.25 | +330.77% | 5 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $29 | $8.86 | +227.31% | 5 | Jul 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $33 → $26 | $2.71 | +859.41% | 3 | Jun 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $12 | $26.98 | -55.52% | 2 | Apr 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $10 | $3.94 | +153.81% | 4 | Apr 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $675 → $400 | $3.01 | +13,189.04% | 2 | Mar 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $42 → $80 | $15.55 | +414.47% | 2 | Dec 8, 2020 |
Equillium
Mar 28, 2025
Downgrades: Market Perform
Price Target: $3 → $1
Current: $1.91
Upside: -47.64%
Q32 Bio
Dec 11, 2024
Downgrades: Market Perform
Price Target: $68 → $9
Current: $1.67
Upside: +438.92%
Aclaris Therapeutics
Nov 19, 2024
Upgrades: Outperform
Price Target: $2 → $7
Current: $2.10
Upside: +233.33%
Alumis
Jul 23, 2024
Initiates: Outperform
Price Target: $29
Current: $4.51
Upside: +543.02%
Cartesian Therapeutics
Apr 23, 2024
Initiates: Outperform
Price Target: $39
Current: $10.75
Upside: +262.79%
Sagimet Biosciences
Mar 25, 2024
Initiates: Outperform
Price Target: $26
Current: $7.11
Upside: +265.68%
RAPT Therapeutics
Feb 21, 2024
Downgrades: Market Perform
Price Target: $80
Current: $12.93
Upside: +518.72%
ABIVAX Société Anonyme
Nov 14, 2023
Initiates: Outperform
Price Target: $20
Current: $88.03
Upside: -77.28%
argenx SE
Mar 3, 2023
Maintains: Outperform
Price Target: $430 → $435
Current: $750.78
Upside: -42.06%
Disc Medicine
Feb 28, 2023
Initiates: Outperform
Price Target: $36
Current: $60.72
Upside: -40.71%
Feb 8, 2023
Maintains: Outperform
Price Target: $9 → $7
Current: $1.75
Upside: +300.00%
Feb 6, 2023
Maintains: Outperform
Price Target: $14 → $21
Current: $17.14
Upside: +22.52%
Jan 9, 2023
Maintains: Outperform
Price Target: $40 → $45
Current: $18.72
Upside: +140.38%
Nov 22, 2022
Initiates: Outperform
Price Target: $6
Current: $7.01
Upside: -14.41%
Nov 9, 2022
Maintains: Outperform
Price Target: $5 → $6
Current: $5.54
Upside: +8.30%
Oct 21, 2022
Downgrades: Market Perform
Price Target: $9 → $5
Current: $0.76
Upside: +557.03%
Aug 25, 2022
Initiates: Outperform
Price Target: $17
Current: $59.44
Upside: -71.40%
Aug 9, 2022
Maintains: Outperform
Price Target: $68 → $64
Current: $22.85
Upside: +180.15%
Aug 9, 2022
Maintains: Outperform
Price Target: $66 → $70
Current: $16.25
Upside: +330.77%
Jul 11, 2022
Maintains: Outperform
Price Target: $50 → $29
Current: $8.86
Upside: +227.31%
Jun 1, 2022
Maintains: Outperform
Price Target: $33 → $26
Current: $2.71
Upside: +859.41%
Apr 28, 2022
Maintains: Outperform
Price Target: $18 → $12
Current: $26.98
Upside: -55.52%
Apr 11, 2022
Maintains: Outperform
Price Target: $15 → $10
Current: $3.94
Upside: +153.81%
Mar 16, 2021
Maintains: Outperform
Price Target: $675 → $400
Current: $3.01
Upside: +13,189.04%
Dec 8, 2020
Maintains: Outperform
Price Target: $42 → $80
Current: $15.55
Upside: +414.47%